Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | CSF1R over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| CSF1R over exp | tenosynovial giant cell tumor | sensitive | Pexidartinib | Phase I | Actionable | In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558). | 26222558 | |
| CSF1R over exp | acute myeloid leukemia | sensitive | Narazaciclib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of acute myeloid leukemia cell lines harboring CSF1R overexpression in culture, and decreased the leukemic burden in the spleen and bone in a patient-derived xenograft (PDX) model (PMID: 38641704). | 38641704 | |
| CSF1R over exp | acute myeloid leukemia | sensitive | Cytarabine + Narazaciclib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of Narazaciclib (ON123300) and Cytosar-U (cytarabine) reduced tumor burden in a patient-derived xenograft (PDX) model of acute myeloid leukemia with CSF1R overexpression (PMID: 38641704). | 38641704 |